CAS: 6879-02-3; Tylocrebrine

该化合物是复杂的有机化合物,其特点是其独特的多环结构,包括二苯基结构,以及有助于其潜在生物活动的复腐性框架.四种甲氧基组(EUOCH3)的存在,增强了其溶性,并可能影响其再活性和与生物目标的相互作用.13aR(13aR)的命名表明,该化学组的具体空间安排可能大大影响化合物的药用特性.这些化合物经常被研究用于医药化学的潜在用途,特别是在开发新型治疗剂方面.此外,复杂的结构可能表现出有趣的电子特性,使其成为材料科学和有机电子学研究的一个主题.

结构式图片

MSDS等安全信息

    上下游产品

    CAS号89978-46-1 1-溴-2-碘-4,5-二甲氧基苯 | CAS号40972-86-9 2,3-二甲氧基苯硼酸

    合成工艺路线路线简述

      📜2,3-二甲氧基苯硼酸置于(1,1'-Bis(Diphenylphosphino)Ferrocene)Palladium(II) Dichloride,三氟代氧化钒(V),叔丁基锂,Sodium Carbonate,三氟乙酸,三氟乙酸酐,Lithium Chloride体系中,用 四氢呋喃,乙二醇二甲醚,二氯甲烷,水,乙酸乙酯 作为反应溶剂,化学反应 19.17H,反应生成 娃兒藤鹼
      参考文献:Synthesis Of Tylocrebrine And Related Phenanthroindolizidines By Vof3-Mediated Oxidative Aryl-Alkene Coupling
      标题:Synthesis Of Tylocrebrine And Related Phenanthroindolizidines By Vof3-Mediated Oxidative Aryl-Alkene Coupling
      摘要:A Highly Convergent Strategy To Prepare Phenanthroindolizidines Is Reported Involving Three Consecutive C-C Coupling Reactions. This Sequence Features A Novel Vof3-Mediated Aryl-Alkene Coupling In The Final Step,Which Enables Regioselective Preparation Of C5-Substituted Phenanthroindolizidines For The First Time. This Strategy Has Been Applied To The Synthesis Of Eight Natural And Unnatural Members In This Class To Investigate The Scope Of This Chemistry And To Explore Structure-Activity Relationships.
      DOI:10.1021/ol1023954

      海关参考信息

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Kirtane AR, Wong HL, Guru BR, Lis LG, Georg GI, Gurvich VJ, Panyam J. Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. Mol Pharm. 2015 Aug 3;12(8):2912-23. doi: 10.1021/acs.molpharmaceut.5b00173.
      2: Zheng Y, Liu Y, Wang Q. Collective asymmetric synthesis of (-)-antofine, (-)-cryptopleurine, (-)-tylophorine, and (-)-tylocrebrine with tert-butanesulfinamide as a chiral auxiliary. J Org Chem. 2014 Apr 18;79(8):3348-57. doi: 10.1021/jo500013e. doi: 10.1021/ol1023954.

      合成参考文献


      摘要:Progress Report Submitted to the National Cancer Institute by Charles Pfizer & Co., -(77), 1964
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知